α5-GABAAアロステル調節は,AMPA受容体経由でドーパミンのニューロン活動を誘発し,延長する
Areebah Ahmed1, Mostafa El Mansari1, Pierre Blier1
1Institute of Mental Health Research, University of Ottawa, ON, Canada.
Journal of psychopharmacology (Oxford, England)
|February 17, 2026
まとめ
α5-GABAA受容体調節剤L-655,708は,ラットのドーパミンニューロン活動を最大1週間増加させます. この抗うつ剤のような効果はAMPA受容体とベンゾジアゼピンサイトによって媒介されます.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- α5-GABAA受容体のネガティブアロステリック調節剤 (NAM) は抑制を軽減し,AMPA受容体の機能を強化する.
- L-655,708はα5-GABAA-NAMであり,ネズミのモデルで迅速かつ持続的な抗うつ剤のような効果を示しています.
研究 の 目的:
- L-655,708がネズミのモノアミンおよびグルタミン酸系に与える影響を調査する.
- 神経化学的変化と観察された抗うつ剤のような反応を相関させるため.
主な方法:
- ネズミはL-655,708 (3 mg/kg, i.p.) の単回投与を受けた. または車両.
- In vivo細胞外記録は,背面のラフェ核,ロカス・コエルーレウス,腹部テグメンタル領域,および中部前頭前皮質で行われました.
- ヒッポカンパのCA1領域のAMPAとNMDAに対する反応性は,マイクロオントフォレシスによって評価されました.
主要な成果:
- L-655,708は海馬におけるNMDA誘発反応を減少させたが,AMPA反応は減少しなかった.
- ベントラ・テグメンタル領域のドーパミンニューロン活動は,注射後最大1週間で倍増しました.
- このドーパミンの増加はフルマゼニルとNBQXによって阻害され,ベンゾジアゼピン部位とAMPA受容体の関与を示した.
結論:
- L-655,708は,最大1週間の間,腹部テグメンタル領域のドーパミンニューロン活動を高めます.
- 観察された効果はAMPA受容体の機能に依存しています.
- このメカニズムはベンゾジアゼピン部位での作用を伴うため,抗うつ薬の作用の新たな経路を示唆している.
キーワード:
L-655,708 について抗うつ剤の抗うつ剤は,抗うつ薬として使われています.ドーパミンは,ドーパミンです.ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とは,ノルアピネフリン (norepinephrine) とはセロトニン・セロトニンとは関連する概念動画
Neurochemical Transmission: Sites of Drug Action
3.7K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.7K
Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.2K
Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Drugs Acting on Autonomic Ganglia: Stimulants
2.1K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.1K
Long-term Potentiation
3.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
3.7K


